I27.0
Conditions
Interventions
Group 1: In the afternoon 10 patients with PAH will be attached to a full cardiorespiratory polysomnography in our university sleep lab. Beyond that they will be attached to a non-invasive hemodynamic
Sponsors
Department für Neurologie - Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: a. Age > 18 years (no age limit) b. able to consent c. Diagnosis of Nizza class I pumonary arterial Hypertension -PAH- according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination for PAH -where there was no treatment with combination therapy in PAH patients then the reason must be documented-
Exclusion criteria
Exclusion criteria: - secondary (postcapillary) pulmonary hypertension (mean pulmonary arterial hypertension > 25 mmHg; PCWP >15 mmHg) -COPD - other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment - severe neurological pre-existing conditions such as stroke, especially brainstem infarction - intake of opioids - severe psychiatric pre-existing conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High frequency component of heart rate variability [%], low frequency component of diastolic blood pressure variability [%] | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate [bpm], systolic blood pressure [mmHG], diastolic blood pressure [mmHG], stroke volume index [L/min/m²], high frequency component of diastolic blood pressure variability[%], low frequency component of heart rate variability [%], respiratory rate [/min], tidal volume [ml], minute ventilation [L/min], oxygen saturation [%], transcutaneous CO2 [mmHG], Borg Dyspnoea Scale [points] | — |
Countries
Germany
Contacts
Public ContactMatthias Boentert
Department für Neurologie- Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster
Outcome results
None listed